Treating blood or blood products with compounds which have a mustard, azirdinium or aziridine group and a nucleic acid binding group
US6410219B1 · kind B1 · utility
31Cited by
35References
78Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2000 |
| Grant date | Jun 25, 2002 |
| Priority date | — |
| Expiry date | Mar 30, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2795/18163
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.